Praesidia publishes study results on Clinell Contiplan
The randomized controlled trial published in BMJ Open showed a 50% reduction in pressure injuries in 20 Australian facilities with 858 patients.
See the latest news and media coverage for Praesidia. We track all announcements, press releases, and industry mentions in real time, all in one place.
Medical device manufacturer and distributor
praesidia.itLast updated
In short: Praesidia reported a study found Clinell Contiplan halved pressure injuries across 20 Australian facilities.
The randomized controlled trial published in BMJ Open showed a 50% reduction in pressure injuries in 20 Australian facilities with 858 patients.
The system reduces the risk of chemotherapy-induced alopecia at the Giovanni Paolo II Hospital.
The system reduces the risk of chemotherapy-induced alopecia, improving the quality of life of patients.
The systems have been installed at Paideia International Hospital and Mater Dei General Hospital, bringing to four simultaneous treatment stations.
Track Praesidia and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Praesidia and other trending companies.